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Abstract
Introduction: The mechanism underlying the spontaneous improvement of rheumatoid arthritis (RA) during
pregnancy and the subsequent postpartum flare is incompletely understood, and the disease course varies widely
between pregnant RA patients. In pregnancy, total and free levels of cortisol increase gradually, followed by a
postpartum decrease to prepregnancy values. The glucocorticoid receptor (GR) polymorphisms BclI and N363S are
associated with relatively increased glucocorticoid (GC) sensitivity, whereas the 9b and ER22/23EK polymorphisms of the
GR gene are associated with a relatively decreased GC sensitivity. We examined the relation between the presence of
these GR polymorphisms and level of disease activity and disease course of RA during pregnancy and postpartum.
Methods: We studied 147 participants of the PARA study (Pregnancy-Induced Amelioration of Rheumatoid Arthritis
study), a prospective study investigating the natural improvement during pregnancy and the postpartum flare in
women with RA. Patients were visited, preferably before pregnancy, at each trimester and at three postpartum
time points. On all occasions, disease activity was scored by using DAS28. All patients were genotyped for the GR
polymorphisms BclI, N363S, 9b, and ER22/23EK and divided in groups harboring either polymorphisms conferring
increased GC sensitivity (BclI and N363S; GC-S patients) or polymorphisms conferring decreased GC sensitivity (9b
or 9b + ER22/23EK; GC-I patients). Data were analyzed by using a mixed linear model, comparing GC-S patients
with GC-I patients with respect to improvement during pregnancy and the postpartum flare. The cumulative
disease activity was calculated by using time-integrated values (area under the curve, AUC) of DAS28 in GC-I
patients versus GC-S patients. Separate analyses were performed according to the state of GC use.
Results: GC-S patients treated with GC had a significantly lower AUC of DAS28 in the postpartum period than did
GC-I patients. This difference was not observed in patients who were not treated with GCs. During pregnancy,
GC-S and GC-I patients had comparable levels of disease activity and course of disease.
Conclusions: Differences in relative GC sensitivity, as determined by GR polymorphisms, are associated with the
level of disease activity in the postpartum period in GC-treated patients, but they do not seem to influence the
course of the disease per se.
Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory dis-
order characterized by chronic synovitis leading to joint
destruction. During pregnancy, spontaneous reduction of
disease activity in RA is common, a phenomenon that is
also observed in other autoimmune disorders [1-5]. After
birth, however, RA deteriorates in the majority of women
[3,4,6]. Pregnancy is supposed to have immunomodulatory
effects, but the exact mechanisms underlying the sponta-
neous amelioration during pregnancy and the subsequent
postpartum flare have still not been elucidated. Several
hypotheses have, however, been put forward, including the
beneficial effect of maternal-fetal HLA-incompatibility
[7,8] and of increased galactosylation of immunoglobulin
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G [9-11]. Shifts in T-cell cytokine secretion profiles also
have been proposed as a potential mechanism underlying
the improvement of RA during pregnancy and the post-
partum deterioration [12-15].
In healthy pregnancy, total and free levels of cortisol
increase progressively, reaching a peak in the second and
third trimesters [16-18]. The improvement in RA starts in
the first trimester, and almost half of patients have at least
low disease activity (DAS28 <3.2) in the third trimester
[4]. Nevertheless, prospectively studied cohorts of preg-
nant RA patients concurrently evaluating reduction of dis-
ease activity with accompanying (free) cortisol levels on an
individual basis are lacking. It is known from daily clinical
practice, however, that interindividual differences in the
degree of pregnancy-induced remission and the postpar-
tum deterioration do exist, with some women reaching
complete remission during pregnancy, whereas others
have persistent active disease. This discrepancy was
already noticed in two early case series in which a cortisol
metabolite (that is, 17-hydroxycorticosteroid (17-OHCS))
was measured in pregnant RA women. High levels of 17-
OHCS related to improvement of disease activity in only a
subset of patients [19,20]. This variation in clinical
responses does not depend solely on the absolute levels of
cortisol but might also be explained by differences in indi-
vidual GC sensitivity.
In the healthy population, a considerable variation in GC
sensitivity has been demonstrated by low-dose (0.25 mg)
dexamethasone suppression tests and functional in vitro
assays [21,22]. In diseased states, these differences in GC
sensitivity are reflected by a wide spectrum of GC therapy
efficacy, which may partly be explained by four functional
single nucleotide polymorphisms (SNPs) in the glucocorti-
coid receptor (GR) gene. The minor alleles of the poly-
morphisms N363S (rs6195) and BclI (rs41423247) are
associated with a relative hypersensitivity to GC, whereas
the ER22/23EK (rs6189 and rs6190) and 9b (rs6198) SNPs
are associated with a relatively decreased GC sensitivity
[23]. Previously, we demonstrated that carriers of the
ER22/23EK variant more often had erosive disease and
more frequently needed tumor necrosis factor-alpha
(TNF-a) blocking therapy [24]. Similarly, these GR poly-
morphisms could explain differences in disease course
during pregnancy and postpartum in RA.
Therefore, the aim of our study was to investigate the
association between GR gene polymorphisms and level of
disease activity and disease course during pregnancy and
in the postpartum period in RA patients.
Materials and methods
Patients
All patients were participants of the PARA study (Preg-
nancy-Induced Amelioration of Rheumatoid Arthritis
study), a nationwide prospective study investigating the
natural improvement of RA during pregnancy and the
postpartum flare [4]. If possible, patients were visited
before conception. Patients were visited at their home
address at each trimester and at 6 weeks, 12 weeks, and
26 weeks after delivery. In the present study, women who
had a miscarriage were excluded from further analysis,
and no woman was included twice.
Data collection
Trained research nurses or physicians examined all patients
by using a standardized 28-joint count for swelling and
pain. Disease activity was calculated by using the disease
activity score (DAS28) with three variables (swollen joint
count, tender joint count and C-reactive protein (CRP)
level) [25], because this variant of the DAS has been shown
to reflect disease activity most reliably during pregnancy
[26]. Current medication use at each visit was recorded. All
mothers provided information on breastfeeding, because
this may interfere with resumption of methotrexate (MTX)
therapy after delivery.
Improvement of disease activity during pregnancy was
defined according to the EULAR criteria as responders
(moderate and good response combined) versus nonre-
sponders and could, in accordance with the EULAR cri-
teria, be applied only to those patients with a baseline
DAS28 ≥3.2 at the first trimester (n = 71) [25]. The
“reversed” EULAR criteria were used to define a very early
flare (deterioration between the visits at the third trimester
and at 6 weeks postpartum), early flare (deterioration
between the visits at 6 weeks and at 3 months postpar-
tum), and late flare (deterioration between the visits at 6
weeks and at 6 months postpartum), as described pre-
viously [4], with minor modifications (see Additional file 1,
Table S1).
Glucocorticoid-receptor polymorphisms
All patients were genotyped for four functional poly-
morphisms of the GR gene (ER22/23EK, rs6189 and
rs6190; N363S, rs6195; BclI, rs41423247 and 9b, rs6198),
by using DNA extracted from samples of peripheral
venous blood. Genotyping was performed by using Taq-
man allelic discrimination assays (Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands), following proto-
cols described by the supplier. Results were analyzed by
using the sequence detection system 2.2 software (Applied
Biosystems).
Data and statistical analysis
Mann-Whitney U tests and c2 tests were used to deter-
mine differences in baseline characteristics.
We estimated DAS28 in patients who used GCs versus
patients who did not use GCs by using a linear mixed
model (LMM). With this model, we compared the area
under the curve (AUC) of DAS28 in the two groups on
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the whole trajectory, during pregnancy, and in the post-
partum period. We used the DAS28 score as the
response, and Time and the Use of glucocorticoid ×
Time interaction as covariates. Time is used as a catego-
ric variable denoting one of the seven measurement occa-
sions. Similarly, we then estimated separate linear mixed
models for each individual polymorphism, by using Time
and the interaction of Time × Carriage of minor alleles
as covariates. Because of the low frequencies of the
N363S (4.1%) and the ER22/23EK (7.5%) carriers, no
AUC of DAS28 could be calculated for these models.
Subjects were therefore further analyzed as carriers of a
polymorphism associated with increased sensitivity for
GCs (BclI and/or N363S, referred to as the GC-S group)
versus carriers of a polymorphism associated with
reduced sensitivity to GCs (9b or 9b + ER22/23EK,
referred to as the GC-I group). Patients who were hetero-
zygous for both the BclI and 9b polymorphisms or the
N363S and 9b variants were excluded from the GC-S/
GC-I groups. In this final model, we again tested whether
the average DAS28 was equal between the GC-S and
GC-I groups on the whole profile, during pregnancy and
postpartum. In all models, we used a person-specific
intercept and assumed that the residual covariance struc-
ture was autoregressive heteroskedastic.
c2 analysis was applied to compare rates of response
during pregnancy and the presence of a very early, early,
or late flare. All previously mentioned analyses were per-
formed in patients who used GCs and in patients who
did not use GCs separately. Patients were designated as
GC-users when patients used GCs during pregnancy and
used GCs at the time of at least two of three postpartum
visits. No correction for multiple comparisons was
applied. Differences in the median daily dosage of predni-
sone given during pregnancy and postpartum were calcu-
lated by using the Mann-Whitney test. Statistical analysis
was performed by using the SPSS version 17.0 and SAS
version 9.2. We considered differences statistically signifi-
cant if P ≤ 0.05 (two-sided).
Ethical approval
All subjects signed informed consent, and the study was
approved by the medical ethics committee of the Eras-
mus Medical Center. This study is in compliance with
the Declaration of Helsinki.
Results
Baseline characteristics
In total, 147 patients participating in the PARA study
were enrolled in the current study. More than 60% of
patients had active disease in the first trimester of their
pregnancy, and all women fulfilled the ACR 1987
revised criteria for RA (Table 1).
As shown previously, sulfasalazine and prednisone
were the most frequently used treatment regimens dur-
ing pregnancy [4]. Approximately 40% of patients did
not use any antirheumatic drug (see Additional file 2,
Table S2). Disease activity scores were available in 69,
115, 133, 142, 140, 137, and 131 women at the seven
different study visits before conception, during preg-
nancy, and postpartum, respectively.
In general, patients treated with GCs (n = 57) had sig-
nificantly higher disease activity than did patients not
treated with GCs (n = 90; Figure 1). Patients who used
GCs had a significantly shorter duration of gestation
and had erosions more frequently (Table 2). Analyses
were therefore performed separately according to the
state of GC use.
Glucocorticoid receptor polymorphisms and disease
course during gestation and postpartum
We found 84 (57.1%) patients who were heterozygous or
homozygous carriers of the BclI polymorphism. The 9b
polymorphism was present in 48 (32.7%) patients.
Analysis of the level of disease activity in carriers ver-
sus noncarriers of these polymorphisms showed that 9b
carriers did not differ significantly in AUC of DAS28
compared with noncarriers (Figure 2A). BclI carriers
treated with GC had a near-significant lower AUC of
DAS28 postpartum compared with noncarriers (P =
0.056; Figure 2B, right panel). No differences in the
AUCs of DAS28 postpartum were observed in non-
GCtreated patients.
Table 1 Patient characteristics
n = 147
Age at delivery in years, mean (SD) 32.4 (3.8)
Disease duration in years, median (range) 5.5 (0.1-28.4)
Gestational age at delivery in weeks, mean (SD) 39.3 (1.9)
Anti-CCP positive, n (%) 87 (59.2)
Rheumatoid factor (IgM) positive, n (%) 110 (74.8)
Presence of erosions, n (%) 105 (71.4)
Number of DMARDs before conception, median (range) 2 (0-6)
Breastfeeding (6 weeks postpartum), n (%) 60 (40.8)
DAS28-CRP3 ≥3.2 in first trimester, n (%)a 71 (61.7)
Moderate/good response during pregnancy, n (%)b 32 (45.1)
Very early flare, N (%)c 29 (21.5)
Early flare, n (%)d 29 (22.0)
Late flare, n (%)e 37 (30.1)
aIn 115 patients, DAS28 in the first trimester was available. bAccording to
EULAR response criteria, DAS28 ≥3.2 in the first trimester is required. Data
were available in c135 , d132, and e123 patients, respectively, according to
reversed EULAR response criteria. Very early flare, deterioration between the
visit at the third trimester and at 6 weeks postpartum; early flare,
deterioration between visits at 6 weeks and at 3 months postpartum; late
flare, deterioration between visits at 6 weeks and at 6 months postpartum;
anti-CCP, anti-cyclic citrullinated protein. DMARDs, Disease-modifying
antirheumatic drugs, including prednisone.
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Nineteen (12.9%) patients were heterozygous carriers of
both the BclI and 9b polymorphisms or the N363S and
9b variants. These patients were excluded in the final
analysis to allow an appropriate comparison between
patients carrying a polymorphism associated with
increased sensitivity to GCs (BclI and/or N363S, GC-S
group) and patients harboring a genetic variant asso-
ciated with reduced sensitivity to GCs (9b or 9b + ER22/
23EK, GC-I group). The results of this analysis, shown in
Figure 2C, indicate that GC treated patients in the GC-I
group had a significantly higher AUC of DAS28 in the
whole postpartum period (that is, up to 26 weeks), than
did patients in the GC-S group (P = 0.046). In patients
not treated with GCs, these differences did not exist.
The AUC of DAS28 during pregnancy, the course of
the disease, EULAR response during pregnancy, and the
presence of a very early flare, early flare, or late flare
with reversed EULAR response criteria, were not asso-
ciated with any GR genotype, although the DAS28 was
lower in the GC-S group than in the GC-I group at all
time points in GC treated patients (Figure 2C).
The GR genotypes were equally distributed among GC
users and non-GC users. The clinical characteristics
between GC-S and GC-I patients, stratified according to
the use of GCs, did not differ, except for the more fre-
quent use of nonsteroidal antiinflammatory drugs
(NSAIDs) in the GC-I group (P = 0.01; Table 3). The med-
ian daily dosage of prednisone given during pregnancy,
taking the highest dosage needed at any time during preg-
nancy, tended to be higher in GC-I patients (8.75 mg daily
versus 6.25 mg daily; P = 0.157). GC-S patients could
more frequently reduce the daily needed GC dose during
pregnancy than could the GC-I patients, possibly reflecting
higher GC sensitivity to the pregnancy-related increase in
cortisol in GC-S patients, although this was not statisti-
cally significant (n = 7, 29.2% versus n = 1, 7.7%; P =
0.130). In the postpartum period, prednisone daily dosages
did not differ between GC-S and GC-I patients.
Discussion
In this nationwide prospective study including 147 preg-
nant RA patients, we examined for the first time whether
GR polymorphisms that modulate GC sensitivity are asso-
ciated with the level of disease activity and disease course
during pregnancy and the postpartum period. We show
that GC treated patients in the GC-S group (that is, those
with the BclI or N363S or both polymorphisms, associated
with relatively increased GC sensitivity) have a significantly
lower disease activity in the postpartum period than do
Figure 1 Disease activity (DAS28 ± SEM) among pregnant
women with (n = 57) and without (n = 90) use of
glucocorticoids.
Table 2 Patient characteristics stratified according to use of glucocorticoids
Use of GCs (n = 57) No use of GCs (n = 90)
Age at delivery in years, mean (SD) 33.15 (3.80) 31.93 (3.67)
Disease duration in years, median (range) 6.07 (0.22-28.57) 5.18 (0.14-28.54)
Gestational age at delivery in weeks, mean (SD) 38.44 (2.30) 39.85 (1.27)f
Anti-CCP positive, n (%) 39 (68.4) 51 (56.7)
Rheumatoid factor (IgM) positive, n (%) 47 (82.5) 63 (70.0)
Presence of erosions, n (%) 49 (86) 56 (62.2)f
Dosage of prednisone (mg/day), median (range) 7.5 (2.5-20) -
Number of DMARDs before conception, median (range) 2 (0-5) 1 (0-4)f
Breastfeeding (6 weeks postpartum), n (%) 13 (22.8) 47 (52.2)f
DAS28 ≥3.2 in first trimester, n (%)a 33 (70.2) 38 (55.9)
Moderate/good response during pregnancy, n (%)b 15 (45.5) 17 (43.6)
Very early flare, n (%)c 9 (17.3) 18 (21.7)
Early flare, n (%)d 9 (18.0) 20 (24.4)
Late flare, n (%)e 10 (21.3) 27 (35.5)
aIn 115 patients, DAS28 in the first trimester was available. bAccording to EULAR response criteria, DAS28 ≥3.2 in the first trimester is required, n = 71 of 115.
cData were available in 135 patients, d132 patients, and e123 patients, according to reversed EULAR response criteria. fP < 0.05 as compared with patients using
GCs. Anti-CCP, anti-cyclic citrullinated protein.
DMARDs, Disease-modifying antirheumatic drugs, excluding prednisone.
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Figure 2 Disease activity according to carriage of GR polymorphisms. (A) Disease activity in carriers of 9b (n = 29) versus noncarriers (n =
61) in patients not using glucocorticoids (GCs) (left panel). Of patients using GCs, 19 were carriers of the 9b polymorphism, and 37 were
noncarriers (right panel). In one patient, the 9b-genotype could not be determined. (B) Disease activity in carriers of BclI (n = 55) versus
noncarriers (n = 34) in patients not using GCs (left panel). In one patient, the BclI-genotype could not be determined. Of patients using GCs, 29
were carriers of the BclI polymorphism, and 28 were WT carriers (right panel). (C) Disease activity in carriers of polymorphisms conferring
increased GC sensitivity (n = 44; GC-S group) versus patients carrying polymorphisms conferring decreased GC sensitivity (n = 15; GC-I group)
not using GC (left panel). Of patients using GC, 24 were in the GC-S group, and 13, in the GC-I group (right panel). Disease activity is presented
as DAS28 ± SEM.
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patients in the GC-I group (9b or 9b + ER22/23EK, asso-
ciated with relatively decreased GC sensitivity), as mea-
sured by the AUC of the DAS28. In patients not treated
with GC, the level of disease activity and disease course
during pregnancy or in the postpartum period does not
seem to be influenced by differences in GR genotype.
Gestational-induced remission of RA has been recog-
nized for a long time [27] and may in part be attributed
to the increase in cortisol production that in turn
enhances endogenous immunosuppression. Pregnancy is
indeed considered to be a natural variant of hypercorti-
solism [28,29] and serum (free) cortisol, urinary free
cortisol, salivary cortisol, and cortisol content in hair all
have been demonstrated to increase progressively during
gestation, followed by a rapid postpartum decrease in
cortisol levels [17,18,30-37].
Apart from cortisol availability, the ultimate biologic
effects of GCs also depend on GC sensitivity, which is
modulated by GR polymorphisms [23].
Based on the course of cortisol levels during preg-
nancy and after delivery, we hypothesized that differ-
ences in glucocorticoid sensitivity might in part explain
why the beneficial effect of pregnancy on RA disease
activity does not occur in all RA patients.
Polymorphisms of the GR gene have been demon-
strated to influence disease course in several inflamma-
tory disorders, including Graves ophthalmopathy [38],
Crohn disease [39], and multiple sclerosis [40]. We
recently demonstrated that the minor alleles of BclI and
9b were associated, respectively, with decreased and
increased susceptibility to develop RA. In addition,
ER22/23EK carriers had a worse disease phenotype and
needed more frequent TNF-a blocking therapy [24]. We
extend these data by demonstrating higher levels of dis-
ease activity in the postpartum period in GC treated
patients in the GC-I group, despite the more frequent
use of NSAIDs.
Interestingly, the differences in disease activity between
carriers of GC-sensitive and GC-resistant polymorphisms
were observed only in women treated with GCs. The GC
treated patients involve a subgroup of women with high
disease activity, as reflected by observed higher DAS28.
Our observations may imply that in the postpartum
phase, when endogenous cortisol levels decrease, patients
with polymorphisms associated with increased GC sensi-
tivity have more benefit from GC therapy. Therefore, in
states of relative glucocorticoid deficiency, differences in
GC sensitivity due to genetic variability may in part
determine variations in disease activity. Conversely, in
patients with low disease activity, as characterized by the
absence of glucocorticoid therapy in our cohort, endo-
genous levels of cortisol apparently can prevent uncon-
trolled inflammatory processes independent of genetic
variations of the GR gene, although we did not measure
cortisol levels in our patients.
This concept of a “relative glucocorticoid deficiency”
might also explain why the observed variation in disease
activity seems to be restricted to the postpartum period,
because Magiakou and co-workers [41] showed that
hypothalamic CRH secretion in healthy pregnant women
Table 3 Clinical characteristics of patients in the GC-S and GC-I groups according to the use of glucocorticoids
Use of GCs No use of GCs
GC-S (n = 24) GC-I (n = 13) GC-S (n = 44) GC-I (n = 15)
Age at delivery in years, mean (SD) 34.1 (3.1) 34.1 (3.6) 31.6 (3.9) 31.2 (3.0)
Disease duration in years, median (range) 4.6 (0.2-28.6) 6.8 (1.0-22.7) 5.3 (0.1-28.5) 2.4 (0.2-28.4)
Gestational age at delivery in weeks, mean (SD) 39.0 (1.9)A 37.4 (2.2) 39.8 (1.3) 39.9 (1.3)
Anti-CCP positive, n (%) 16 (66.7) 8 (61.5) 24 (54.5) 6 (40%)
Rheumatoid factor (IgM) positive, n (%) 17 (70.8) 10 (76.9) 31 (70.5) 9 (60.0)
Presence of erosions, n (%) 22 (91.7) 13 (100) 28 (63.6) 8 (53.3)
Dosage of prednisone (pregnancy; mg/day), median (range) 6.25 (2.5-15) 8.75 (5-20) - -
Dosage of prednisone (postpartum; mg/day), median (range) 8.75 (2.5-15) 10.0 (5-15) - -
Number of DMARDs before conception, median (range) 2 (0-4) 2 (1-5) 2 (0-4) 2 (0-3)
Moderate/good response during pregnancy, n (%) 5/11 (45.5) 4/9 (44.4) 8/16 (50) 5/11 (45.5)
Very early flare, N/Ntotal (%) 5/21 (23.8) 3/13 (23.1) 10/41 (24.4) 5/13 (38.5)
Early flare, N/Ntotal (%) 4/21 (19.0) 2/12 (16.7) 12/40 (30.0) 3/13 (23.1)
Late flare, N/Ntotal (%) 4/19 (21.1) 4/13 (30.8) 15/37 (40.5) 4/12 (33.3)
Breastfeeding (6 weeks postpartum), n (%) 8 (33.3) 1 (7.7) 20 (45.5) 8 (53.3)
Use of NSAIDs at 6 months postpartum,a N/Ntotal (%) 7/22 (31.8)
b 10/13 (76.9) 13/40 (32.5) 6/13 (46.2)
Use of MTX at 6 months postpartum,a N/Ntotal (%) 11/22 (50.0) 9/13 (69.2) 10/40 (25.0) 5/13 (38.5)
Use of sulfasalazine at 6 months postpartum,a N/Ntotal (%) 6/22 (27.3) 2/13 (15.4) 17/40 (42.5) 6/13 (46.2)
Use of anti-TNF-a at 6 months postpartum,a N/Ntotal (%) 3/22 (13.6) 3/13 (23.1) 2/40 (5.0) 0/13 (0)
Data concerning response during pregnancy, very early flare, early flare, and late flare were present in 47, 88, 86, and 81 patients, respectively. aAvailable in 88
patients. bP < 0.05 compared with GC-I, use of GC. Anti-CCP, anti-cyclic citrullinated protein; TNF-a, tumor necrosis factor-alpha.
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is transiently suppressed at 3 and 6 weeks, recovering
only at 12 weeks postpartum. This suppression of the
hypothalamic-pituitary-adrenal (HPA) axis in the post-
partum period, which could be even more pronounced in
RA in which a preexisting blunted HPA axis is described
in nonpregnant states [42], might even further attenuate
the ability of the HPA axis to produce sufficient levels of
cortisol.
The clinical relevance of this blunted HPA axis in the
first 3 months after childbirth is illustrated by a higher
incidence or exacerbation of several autoimmune dis-
eases, including postpartum depression, autoimmune
thyroid disease, and rheumatoid arthritis itself [41,43-46].
The lack of differences between GC-I and GC-S patients
in disease activity during pregnancy could also be
explained by altering levels of glucocorticoid sensitivity,
as was suggested by Majzoub and co-workers [47,48].
Alternatively, patients in the GC-I group tended to need
higher daily dosages of GCs during pregnancy, which
could have masked a higher level of disease activity in
this subgroup of patients. Although we focused on gluco-
corticoids, absolute levels of estrogens and progesterone
also increase progressively during gestation. Both estro-
gens and progesterone possess antiinflammatory proper-
ties and are therefore likely to have substantially
influenced the disease course [49]. Similar to differences
in GC sensitivity, one could speculate that variation in
sensitivity to the immunosuppressing effects of estrogens
and progesterone might also contribute to the wide clini-
cal spectrum of changes in disease activity observed in
pregnancy and after delivery in RA.
Interestingly, the difference in disease activity between
GC-I and GC-S patients persisted during the entire post-
partum follow-up period (that is, up to 26 weeks). Future
studies should examine at which time points disease
activity patterns of both groups converge to prepreg-
nancy levels.
It should be noted that our study also has some limita-
tions. First, genetic-association studies usually require lar-
ger numbers of patients. Although this is the largest
prospectively studied cohort of pregnant RA patients,
additional studies are needed to validate our findings.
Second, the presented data are based on Caucasian
patients only, who may differ from patients from other
geographic areas with different genetic and environmental
backgrounds. Third, parameters of HPA axis activity, not
measured in this study, could have provided additional
information in the non-GC treated patients.
Although the pattern of cortisol levels in pregnancy
and after delivery has been extensively documented
[17,18,30-37], large prospective studies evaluating cortisol
levels along with clinical responses during pregnancy and
postpartum in RA are currently lacking. Together with
new insights in the past two decades supporting a
blunted HPA axis in RA, this justifies renewed interest in
the precise role of GC in pregnant RA patients and the
course of disease [42,50]. In this context, long-term
indices of HPA axis activity, as measured by means of
cortisol in hair, together with dynamic functional assays
to assess GC sensitivity (that is, GR number, affinity of
the GR receptor, and GR-mediated gene transcription)
are promising techniques to unravel further the role of
GCs and the precise contribution to pregnancy-asso-
ciated alterations in disease activity in RA.
Conclusions
We demonstrate that differences in GC sensitivity, as
determined by GR polymorphisms, might influence the
level of disease activity in the postpartum period in GC
treated women. The course of the disease itself does not
seem to be associated with polymorphisms of the GR. In
the light of the relatively small numbers of patients in
each genotype group, however, our data should be
regarded as an interesting new hypothesis possibly add-
ing to the elucidation of the multifactorial mechanisms
underlying pregnancy-induced amelioration and the
postpartum flare, but the data do not necessarily prove
the genetic association. Therefore, future (larger) studies
should validate our hypothesis and examine both para-
meters of glucocorticoid availability and parameters of
glucocorticoid sensitivity in relation to individual disease
courses of pregnant RA patients.
Additional material
Additional file 1: Table S1. Reversed EULAR response criteria for the
definition of postpartum deterioration. This table shows the
conditions for classifying patients as having no flare or a moderate or
severe flare.
Additional file 2: Table S2. Medication use. This table gives an
overview of the different antirheumatic drugs (prednisone, NSAIDs,
DMARDs, and biologicals) used by the patients at different stages of
pregnancy and postpartum.
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